ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Cardiol Therapeutics Inc

Cardiol Therapeutics Inc (CRDL)

1.165
0.085
(7.87%)
Cerrado 10 Marzo 2:00PM
1.0707
-0.0943
(-8.09%)
Fuera de horario: 6:43PM

Calls

StrikeCompraVentaUltimo PrecioP. MedioVariaciónVariación %VolumeInt AbiertoÚltimo Operado
2.500.050.050.010.05-0.04-80.00 %05,165-
5.000.050.750.050.400.000.00 %0171-

Su centro para precios en tiempo real, ideas y debates en vivo

Puts

StrikeCompraVentaUltimo PrecioP. MedioVariaciónVariación %VolumeInt AbiertoÚltimo Operado
2.501.051.551.501.300.000.00 %041-
5.003.704.002.853.850.000.00 %010-

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
ABLVAble View Global Inc
US$ 1.73
(137.18%)
5.14M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
482.05M
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
622.67M
DWTXDogwood Therapeutics Inc
US$ 6.63
(49.66%)
25.92M
KZIAKazia Therapeutics Ltd
US$ 1.1899
(40.80%)
4.5M
ALBTAvalon GloboCare Corporation
US$ 6.96
(-36.15%)
577.55k
SCNXScienture Holdings Inc
US$ 1.55
(-35.68%)
1.59M
ACXPAcurx Pharmaceuticals Inc
US$ 0.4572
(-29.88%)
1.18M
RETOReTo Eco Solutions Inc
US$ 5.42
(-27.73%)
108.27k
OCTOEightco Holdings Inc
US$ 1.08
(-27.03%)
336.99k
BTOGBit Origin Ltd
US$ 0.6117
(118.46%)
622.67M
SUNESUNation Energy Inc
US$ 0.402999
(127.55%)
482.05M
NVDANVIDIA Corporation
US$ 112.69
(1.92%)
341.94M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 10.675
(-0.70%)
143.04M
ICONIcon Energy Corporation
US$ 0.169898
(17.17%)
142.23M

CRDL Discussion

Ver más
Monksdream Monksdream 1 día hace
CRDL, under $2
👍️0
Monksdream Monksdream 2 semanas hace
CRDL, new 52 week low
👍️0
Monksdream Monksdream 3 meses hace
CRDL, under $2
👍️0
MahinAgency MahinAgency 3 meses hace
NASDAQ: $CRDL SHORT SQUEEZE ALERTS

Financial Strategy: With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60
👍️0
MahinAgency MahinAgency 3 meses hace
NASDAQ: $CRDL

Cardiol Therapeutics MAvERIC-Pilot Study Results:

Safety: High tolerability and 95% compliance.

Next Steps: Data supports advancing to Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials
👍️0
MahinAgency MahinAgency 3 meses hace
A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?
👍️0
MahinAgency MahinAgency 3 meses hace
NASDAQ: $CRDL

Advancement: Results support Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials, expanding accessibility to non-immunosuppressive oral therapy.

Short Squeeze Alerts $CRDL, BIG OPPORTUNITY
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL

Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL Pick Up This Morning Short Sueeze Aler

 MAvERIC-Pilot Results:
Safety: High tolerance, 95% compliance.
Next Steps: Advancing to Phase II/III MAVERIC-2 and Phase III MAVERIC-3 trials
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL MAvERIC-Pilot Study:

Efficacy: Significant reductions in pericarditis pain (mean score 5.8 to 1.5) and inflammation (CRP normalized in 80% of patients). Episodes dropped from 5.8/year to 0.9 during the trial.

👍️0
MahinAgency MahinAgency 4 meses hace
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
👍️0
MahinAgency MahinAgency 4 meses hace
INSIDER BUYING : Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.
👍️0
MahinAgency MahinAgency 4 meses hace
$CRDL Here are the MAvERIC-Pilot study results that we’ve been waiting for! 

❤️Marked and rapid reductions in both pericarditis pain and inflammation  maintained throughout the 26-week study!

❤️Episodes of pericarditis per year substantially reduced 

❤️MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2
and the Phase III MAVERIC-3 clinical trials

Congratulations to all long term shareholders! 
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL BIG NEWS:

Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
👍️0
MahinAgency MahinAgency 4 meses hace
Breaking News: NASDAQ: $CRDL unveils groundbreaking results for CardiolRx™ at the American Heart Association Conference! 📷 Rapid pain relief, 85% fewer recurrences, and lasting inflammation reduction.
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

Valued at $9 per share, assuming $609M in sales

Valued at $1 per share, assuming $132M in sales
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL RED TO GREEN, Looks Good

Cardiol Therapeutics Inc Today at 11:15am EST Dr. Allen Luis MayoClinic will present the Pericarditis full clinical data at #AHA2024
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL SHORT SQUEEZE ALERTS, STAY TUNED

Addressing urgent unmet medical needs: CardiolRx™ targets acute myocarditis, a life-threatening condition with no FDA-approved treatments
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

 Valued at $9 per share, assuming $609M in sales by 2033

Valued at $1 per share, assuming $132M in sales by 2033
👍 1
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

Recently raised $13.5 million to fund developments?, SHORT SQUEEZE ALERTS
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL lets See Red To Green, 

H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

The company recently raised $13.5 million
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL The company recently raised $13.5 million, ensuring financial backing for ongoing clinical developments and corporate growth
👍️0
MahinAgency MahinAgency 4 meses hace
Picked up NASDAQ: $CRDL this morning…low float runner on news incoming… Short Squeeze Alerts

The 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis
👍️0
tw0122 tw0122 4 meses hace
30 million shares offering at .26 October 30th
👍️0
MahinAgency MahinAgency 4 meses hace
H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis patients post-IL-1 blocker therapy.
👍️0
MahinAgency MahinAgency 4 meses hace
$CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL SHORT SQUEEZE ALERTS

H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics with a price target of $9.00.

MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis patients post-IL-1 blocker therapy.
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL Financial Strategy: With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price,aiming for a target of $10 per share (C$13.60
👍️0
MahinAgency MahinAgency 4 meses hace
Key Points:

Rating & Price Target: H.C. Wainwright maintains a "Buy" rating for Cardiol Therapeutics (CRDL) with a price target of $9.00.
New Trial: MAVERIC-2 trial aims to assess CardiolRx in recurrent pericarditis (RP) patients post-IL-1 blocker therapy.
Market Advantage: CardiolRx could serve as an earlier treatment alternative, competing with Arcalyst, which costs $300,000 annually.
Strategic Expansion: By targeting unmet needs in the RP market, CardiolRx is positioned to broaden its market potential.
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.

Recently raised $13.5 million to fund developments?
👍️0
MahinAgency MahinAgency 4 meses hace
Big coming Next week 💃💃💃💃
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL
ARCHER trial completed enrollment, with results expected in Q1 2025. Orphan status could lead to $120M peak sales 

Promising early results, potential approval by 2027, targeting $609M peak sales

👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60

$CRDL BIG SHORT SQUEEZE 
👍️0
tw0122 tw0122 4 meses hace
Chart looking good $2.07 next targets $4
👍️0
glenn1919 glenn1919 4 meses hace
CRDL........................https://stockcharts.com/h-sc/ui?s=CRDL&p=W&b=5&g=0&id=p86431144783
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL up over 220% year-to-date; analysts raised the price target from $4.50 to $11.00, keeping a "Speculative Buy" rating.

👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL 12-Month Price Target: $10 based on a sum-of-the-parts valuation.

Cardiol had around $21 million in cash at the end of Q1 


👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL
 Cardiol Therapeutics recently reported encouraging outcomes from its Phase II MAvERIC trial of CardiolRx, an ultra-pure oral cannabidiol formulation for recurrent pericarditis.

The 12-month price target is $10
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: CRDL is advancing CardiolRx™ for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL CEO Investment: Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each, indicating strong personal conviction in the company's potential.
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL With about $21 million in cash, the company may consider a small capital raise if new data boosts the stock price, aiming for a target of $10 per share (C$13.60
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL is advancing CardiolRx™ for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million

👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL A target of $10 per share (approximately C$13.60) is proposed, indicating a potential upside of over 5x within a year, contingent on strong data readouts for CardiolRx™?
👍️0
MahinAgency MahinAgency 4 meses hace
Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities.
👍️0
MahinAgency MahinAgency 4 meses hace
$CRDL Insider Buying: Cardiol CEO David Elsley purchased approximately $100,000 in shares at about $2.03 each
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL Cardiol Therapeutics sets a 12-month price target of $10, valuing CardiolRx at $9 for recurrent pericarditis and $1 for acute myocarditis, based on projected sales and associated probabilities
👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL 12-month price target is $10, with $9 attributed to recurrent pericarditis and $1 to acute myocarditis

👍️0
MahinAgency MahinAgency 4 meses hace
NASDAQ: $CRDL is advancing CardiolRx for acute myocarditis and recurrent pericarditis, both in Phase II trials. The company raised $13.5 million

Cardiol sets a 12-month price target of $10
👍️0